KZR
Kezar Life Sciences, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.77
P/S
0.00
EV/EBITDA
0.32
DCF Value
$9.69
FCF Yield
-95.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-64.4%
ROA
-73.1%
ROIC
-72.2%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-14.5M | $-1.99 |
| FY 2025 | $0.00 | $-56.0M | $-7.66 |
| Q3 2025 | $0.00 | $-11.2M | $-1.53 |
| Q2 2025 | $0.00 | $-13.7M | $-1.87 |
Analyst Ratings
View AllConsensus
Hold
Target (Consensus)
$6.00
Target (Median)
$6.00
Target Range
$5.00 - $7.00
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.43
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.